Mineralys Therapeutics, Inc., which launched the largest biopharmaceutical company initial public offering so far this year late on 9 February, was an ideal IPO candidate under current market conditions and investors enthusiastically supported the company’s public market debut. With positive Phase II results in November and plans to move its hypertension drug candidate into Phase III, Mineralys has an asset with upcoming milestones to keep investors interested.
Finance Watch: Mineralys Raises $192m In Year’s Biggest IPO So Far
Despite Market’s Embrace, Restructuring Continues
Public Company Edition: Mineralys launches the second $100m-plus initial public offering of 2023 and trades higher in its first day. Also, Collegium sells $210m worth of notes, Eliem cuts 55% of its jobs at it shifts to preclinical and Aligos de-prioritizes hepatitis B while reducing its workforce another 10%.
More from Financing
More from Business
• By
The triple therapy improves lung function in the Phase III KALOS and LOGOS studies
• By
As biopharma derisks its business with China ‘rebalancing’ strategies, Syngene could convert majority of such pilots into full program contracts amid a challenging FY2025. The CRDMO also expects business discussions pertaining to a newly acquired US biologics site to mature into commercial opportunities.
• By
Biogen expects little impact from existing tariffs and any that may apply if the US exemption of pharma products is lifted, since 75% of its manufacturing is in the US and 55% of sales are ex-US.